Techno Drugs Ltd.
DDSE:TECHNODRUG33.30
BDT
+1.00
(+3.10%)
ISIN
BD0499TDL002
Return %
Stock
S&P 500
1Y
11.00
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Shah Jalal Uddin Ahmed
- Full Time Employees
- 1,438
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Jul 14, 2024
- Website
- technodrugsltd.com
- Similar Companies
- Business
- Techno Drugs Ltd. is a Bangladesh-based pharmaceutical company engaged in the development, formulation, manufacturing, and marketing of human pharmaceuticals, specialized reproductive healthcare solutions, and veterinary medicines. The company operates across two primary business segments: Human Health and Animal Health. Its human healthcare product portfolio includes oncology therapeutics such as cytotoxic injectables and anti-cancer formulations; hormonal and reproductive healthcare products, including subdermal single-rod and double-rod contraceptive implants and injectable contraceptives; broad-spectrum antibiotics; cardiovascular drugs; anti-diabetic medications; anesthetic preparations; and nutritional and metabolic supplements sold under brand names such as 5-Fluril, Neo Zinc, and Neovitan. Its animal health segment offers veterinary pharmaceuticals, including anthelmintics, poultry feed supplements, and livestock antimicrobials. Established in 1996 and headquartered in Dhaka, Bangladesh, the company conducts manufacturing operations at its facilities located in Narsingdi and Gazipur, serving private healthcare sectors, international export markets, and public healthcare programs including the Directorate General of Family Planning under the Ministry of Health and Family Welfare. In recent strategic developments, Techno Drugs Ltd. completed its initial public offering on the Dhaka Stock Exchange and Chittagong Stock Exchange in July 2024 under the ticker TECHNODRUG, raising Tk 100 crore through the book-building method to fund machinery acquisition, loan repayment, and the balancing, modernization, rehabilitation, and expansion of its Narsingdi and Gazipur manufacturing units; commissioned South Asia's first commercial manufacturing plant for single-rod contraceptive implants in September 2025; and initiated a Tk 50 crore bond issuance in 2026 to optimize its capital structure and refinance existing banking debt.